Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Plasma Exchange for COVID-19 Hyperviscosity
NCT04441996Phase 4Completed
- Sponsor
- Emory University
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Emory University. Primary endpoints: Plasma Viscosity at Day 4 and Cumulative Incidence of Adverse Events. Started Jul 2020; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04441996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441996.